The Trump administration's December 2025 executive order directed expedited rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act. In April 2026, the acting attorney general issued a final order immediately moving FDA-approved products and state-licensed medical marijuana into Schedule III while launching a new expedited DEA administrative hearing on broader rescheduling. That hearing convened June 29 and concluded by July 15, 2026, allowing the administrative law judge to receive evidence on medical use, abuse potential, and dependence before a recommended decision and potential final rulemaking. Remaining steps include agency review of the record, possible public comment, and formal publication of any rule, with timelines subject to procedural requirements and potential legal challenges. These developments shape trader assessments of completion dates for full rescheduling.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado$784,600 Vol.
30 de setembro
14%
31 de dezembro
25%
$784,600 Vol.
30 de setembro
14%
31 de dezembro
25%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Mercado Aberto: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...The Trump administration's December 2025 executive order directed expedited rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act. In April 2026, the acting attorney general issued a final order immediately moving FDA-approved products and state-licensed medical marijuana into Schedule III while launching a new expedited DEA administrative hearing on broader rescheduling. That hearing convened June 29 and concluded by July 15, 2026, allowing the administrative law judge to receive evidence on medical use, abuse potential, and dependence before a recommended decision and potential final rulemaking. Remaining steps include agency review of the record, possible public comment, and formal publication of any rule, with timelines subject to procedural requirements and potential legal challenges. These developments shape trader assessments of completion dates for full rescheduling.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado



Cuidado com os links externos.
Cuidado com os links externos.
Frequently Asked Questions